Core Viewpoint - The major shareholder of Saily Medical, Shanghai Angze Private Fund Management Co., Ltd., plans to reduce its stake in the company by up to 4.2028 million shares, representing no more than 2% of the total share capital, due to its own investment planning arrangements [1] Summary by Categories Shareholder Actions - The reduction of shares will occur between October 30, 2025, and January 29, 2026 [1] - The shares will be sold through centralized bidding and block trading methods, with a maximum of 2.1014 million shares to be sold via each method [1] Financial Implications - The planned reduction does not set a price range for the shares being sold [1]

格隆汇9月30日丨塞力医疗（维权）(603716.SH)公布，上海盎泽根据自身投资规划安排，计划于本公告 披露日起15个交易日后的三个月（即2025年10月30日至2026年1月29日），通过集中竞价、大宗交易方 式减持不超过所持公司股份420.28万股，占公司总股本的2%（若减持期间发生送股、资本公积金转增 股本、可转债转股等导致股本变动事项的，拟减持的比例不变，减持数量将根据公司总股本的变动进行 相应调整）。 ...

人民财讯9月30日电，塞力医疗（603716）9月30日公告，持股5.76%的股东上海盎泽私募基金管理有限 公司-盎泽太盈六号私募证券投资基金计划通过集中竞价、大宗交易方式减持不超过所持公司股份 420.28万股，占公司总股本的2%。 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.11% on September 30, with C Jianfa leading the drop [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Baiyang Pharmaceutical (301015) with a closing price of 28.00, up 1.93% [1] - Saily Medical (603716) at 24.87, up 1.84% [1] - Guofa Co., Ltd. (600538) at 5.63, up 1.26% [1] - C Jianfa (301584) was the biggest loser, closing at 28.99, down 15.04% with a trading volume of 264,700 shares and a turnover of 817 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 239 million in main funds, while retail investors contributed a net inflow of 219 million [2][3] - The main funds showed varying net inflows and outflows across different stocks, with Saily Medical experiencing a net inflow of approximately 889,790 and Baiyang Pharmaceutical seeing a net inflow of 738,150 [3]

Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.04%, reaching 25.65 CNY per share, with a trading volume of 267 million CNY and a turnover rate of 5.12%, resulting in a total market capitalization of 5.39 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business involves centralized marketing and service for medical testing, as well as the agency and independent research, production, and sales of in vitro diagnostic products [1] - The revenue composition of Selys Medical includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of the top ten circulating shareholders of Selys Medical, data shows that a fund under Caitong Fund ranks among the top ten shareholders. The Caitong Advantage Industry Rotation Mixed A Fund (011201) entered the top ten shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares [2] - The Caitong Advantage Industry Rotation Mixed A Fund (011201) was established on February 9, 2021, with a latest scale of 536 million CNY. Year-to-date returns are 19.74%, ranking 4636 out of 8167 in its category; the one-year return is 22.47%, ranking 4803 out of 8010; and since inception, it has a loss of 27.14% [2]

Core Viewpoint - The company is focusing on transforming its traditional medical supply chain services into intelligent medical solutions while balancing short-term losses with long-term strategic goals [1] Group 1: Strategic Initiatives - The company is strategically positioning itself in the automated upgrade track of the microbiological testing field, collaborating with COPAN to introduce the first domestic AI recognition system for microbiology [1] - The company has launched a domestically registered microbiological sample preprocessing system, WASP-XPS, in response to the "Made in China" initiative, aiming to enhance its competitive edge against international brands [1] Group 2: Collaborative Projects - In early 2025, the company will collaborate with Shanghai Huashan Hospital and other institutions to establish an "Automated Drug Sensitivity Testing Platform + Intelligent AI Model Drug Sensitivity Diagnosis System" [1] Group 3: R&D Progress - The company is advancing its therapeutic hypertension vaccine, HJY-ATRQβ-001, which is recognized as a national Class I innovative biological drug and is set to enter clinical research by May 28, 2025 [1] - The vaccine aims to provide long-lasting and stable blood pressure control, addressing the limitations of traditional oral medications that require daily administration [1] - The company is also exploring other therapeutic vaccines targeting hypertension, hyperlipidemia, type 2 diabetes, and obesity, which have completed preclinical conceptual validation [1]

从资金流向上来看，当日医药商业板块主力资金净流入1486.86万元，游资资金净流出7521.88万元，散户 资金净流入6035.02万元。医药商业板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 301584 | C建发致 | 8225.62万 | 8.49% | -2828.35万 | -2.92% | -5397.28万 | -5.57% | | 600998 | 九州通 | 2389.11万 | 16.23% | -1071.49万 | -7.28% | -1317.63万 | -8.95% | | 600511 | 国药股份 | 895.78万 | 9.93% | -1003.50万 | -11.13% | 107.72万 | 1.19% | | 002589 | 瑞康医药 | 806.52万 | 19.20% | -436.26万 | -10.39% | -370.25万 | -8 ...

Group 1 - The pharmaceutical commercial sector experienced a decline of 1.81% on September 19, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] - A table detailing the individual stock performance within the pharmaceutical commercial sector was provided [1] Group 2 - The net outflow of main funds in the pharmaceutical commercial sector was 800 million yuan, while speculative funds saw a net inflow of 368 million yuan, and retail investors had a net inflow of 432 million yuan [2] - A table showing the fund flow for individual stocks in the pharmaceutical commercial sector was included [2]

Market Overview - The Shanghai Composite Index decreased by 0.03% at the close, with a trading volume of 979.60 million shares and a turnover of 15,108.13 billion yuan, representing a 12.16% decrease from the previous trading day [1] Industry Performance - The coal industry showed the highest increase at 1.97%, with a transaction amount of 111.71 billion yuan, up 41.65% from the previous day, led by Huayang Co., which rose by 8.09% [1] - The defense and military industry increased by 1.66%, with a transaction amount of 431.15 billion yuan, up 6.87%, led by Guorui Technology, which rose by 9.99% [1] - The non-ferrous metals sector rose by 1.42%, with a transaction amount of 597.97 billion yuan, down 14.34%, led by Ganfeng Lithium, which increased by 10.00% [1] - The automotive sector experienced the largest decline at 1.63%, with a transaction amount of 1,040.70 billion yuan, down 7.43%, led by Haon Automotive, which fell by 11.48% [2] - The pharmaceutical and biological sector decreased by 1.04%, with a transaction amount of 682.17 billion yuan, down 8.78%, led by Saily Medical, which fell by 6.22% [2] - The real estate sector declined by 0.97%, with a transaction amount of 242.96 billion yuan, down 8.46%, led by Suning Universal, which decreased by 10.12% [2]

Group 1 - The actual controller of the company, Mr. Wen Wei, has completed the release of 5,300,000 shares previously pledged to Zhejiang Ideal Microfinance Co., Ltd, resulting in zero pledged shares remaining [2][3][4] - As of the announcement date, the controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd, has pledged a total of 16,000,000 shares, accounting for 73.93% of its holdings and 7.61% of the company's total share capital [2][4] - The company confirms that there are no risks of non-operational fund occupation, illegal guarantees, or related party transactions that could harm the company's interests [4][5] Group 2 - The company plans to hold a half-year performance briefing on September 29, 2025, to discuss its operating results and financial status for the first half of 2025 [8][9] - Investors can submit questions for the briefing from September 22 to September 26, 2025, and the company will address common concerns during the session [9][10] - The briefing will be conducted online through the Shanghai Stock Exchange Roadshow Center, allowing for interactive communication with investors [11][12] Group 3 - The company has issued a correction regarding its announcement on September 18, 2025, concerning capital increase and related party transactions with its actual controller [15][16] - The corrected announcement includes details about the shareholding structure of the target company post-acquisition [16][18] - The company expresses apologies for any inconvenience caused by the correction and commits to improving the quality of its information disclosure [16][18]